AbbVie Inc. Revenue in 2024

AbbVie Inc. reported $56.3B in revenue for fiscal year 2024. This represents a growth of 3.6% compared to the 2023 figure of $54.3B.

AbbVie's $56.3 billion in 2024 revenue is almost identical to its 2021 figure of $56.2 billion — three years of essentially flat top-line performance that masks an extraordinary internal transformation. Humira revenue was declining rapidly in that period as biosimilars entered the U.S. Market in 2023. The fact that total revenue held flat means Skyrizi, Rinvoq, and the Allergan aesthetics portfolio grew fast enough to replace Humira's lost sales essentially dollar for dollar. The $4.3 billion net income figure represents a 7.6 percent net margin on $56.3 billion in revenue — compressed by the interest expense on the debt carried from the Allergan acquisition and the ongoing costs of building out the next product generation. The $320 billion market capitalization prices in the expectation that Skyrizi and Rinvoq's growth trajectories will carry the company to substantially higher revenues over the next five years as the immunology market continues expanding. The 2024 acquisitions of ImmunoGen and Cerevel Therapeutics added oncology and neuroscience assets that won't contribute meaningfully to revenue for years. AbbVie is front-loading pipeline investment while managing the Humira revenue decline — a capital allocation decision that compresses current earnings in exchange for future growth optionality. Management has publicly projected that Skyrizi and Rinvoq will together exceed $27 billion in revenue by 2027, a figure that would require sustained 20-plus percent annual growth from both drugs. The company has maintained its dividend through every phase of the post-Humira transition, a signal of confidence in cash generation that the market has largely credited. Whether the Allergan aesthetics business, which depends heavily on consumer spending on discretionary medical procedures, can sustain growth during economic slowdowns is the variable that most analysts flag as the swing factor in whether the $320 billion valuation proves justified.